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ABSTRACT A model of the endothelin G-protein-coupled receptor (ETA) has been constructed using a segmented ap-
proach. The model was produced using a bovine rhodopsin model as a template for the seven transmembrane -helices. The
three cytoplasmic loop regions and the C-terminal region were modeled on NMR structures of corresponding segments from
bovine rhodopsin. The three extracellular loops were modeled on homologous loop regions in other proteins of known
structure. The N-terminal region was modeled as a three-helix domain based on its homology with a hydrolase protein. To
test the model, the FTDOCK algorithm was used to predict the ligand-binding site for the crystal structure of human
endothelin. The site of docking is consistent with mutational and biochemical data. The principal sites of interaction in the
endothelin ligand all lie on one face of a helix that has been implicated by structure-activity relationship studies as being
essential for binding. As further support for the model, attempts to dock bigET, an inactive precursor to endothelin that does
not bind to the receptor, found no sites for tight binding. The model of the receptor-ligand complex produced forms a basis
for rational drug design of agonists and antagonists for this G-protein-coupled receptor.
INTRODUCTION
Human endothelin-1 (ET-1) is a 21-amino acid polypeptide
(Yanagisawa et al., 1988) that is cross-linked by two disul-
fide bonds and is the most potent vasoconstrictor yet char-
acterized. The structure of ET-1 has been determined by
x-ray crystallography (Janes et al., 1994). ET-1 is processed
from a large precursor protein via the formation of a 38-
residue intermediate called bigET-1 (Warner et al., 1994),
which is biologically inactive. At least three different but
highly homologous isoforms of human ET have been
isolated.
The endothelins are important regulators of the vascular
system and appear to be involved in the pathophysiological
mechanism of a number of vascular conditions, including
hypertension (Kohno et al., 1991), acute renal failure (Shi-
bouta et al., 1990), and angina pectoris (Toyooka et al.,
1991). They act via a G-protein-coupled receptor (GPCR)-
mediated signal transduction pathway. The specific receptor
to which ET-1 binds is a seven transmembrane helical
protein (7TMS) called ETA. This receptor is distinguished
from the highly homologous ETB receptor by its ability to
discriminate between the various ET isoforms (Sakamoto et
al., 1993).
GPCRs are integral membrane proteins that are charac-
terized by the presence of seven hydrophobic domains,
usually ranging in length from 20 to 25 residues, which
represent the transmembrane regions of this large superfam-
ily of proteins. Members of the superfamily are found in a
wide range of organisms and are responsible for the trans-
mission of a variety of signals to the interior of the cell. The
signals can be activated initially by small peptides, amino
acid derivatives, lipid analogs, or stimuli such as odor, light,
and taste, depending on the receptor type. The activated
cascade then passes information to the inside of the cell via
interaction of the receptor with heterotrimeric G-proteins.
Knowledge of the three-dimensional structures of GPCRs
is essential for our understanding of their function and for
the rational design of drugs. Electron diffraction and elec-
tron microscopy (EM) studies have succeeded in determin-
ing the structure of a GPCR-like 7TMS protein, bacterio-
rhodopsin (BR), at medium resolution (Henderson et al.,
1990; Gregorieff et al., 1996), and one GPCR, rhodopsin, at
low resolution (Unger and Schertler, 1995; Unger et al.,
1997). The x-ray crystallographic structure of BR has also
been determined at high resolution from microcrystals
grown in a cubic lipidic phase (Edman et al., 1999; Luecke
et al., 1999). However, until recently there has been no
high-resolution structural information on any GPCR (see
Note added after submission). Consequently, a number of
model-building studies have been undertaken to produce
GPCR structures (for example, Findlay and Eliopoulos,
1990; Grotzinger et al., 1991; Hibert et al., 1991; Ijzerman
et al., 1992; Lewell, 1992; Cronet et al., 1993; Sylte et al.,
1993; Yamamoto et al., 1993; Zhang and Weinstein, 1993;
Van Rhee et al., 1995; Pogozheva et al., 1997; Baldwin et
al., 1997; Herzyk and Hubbard, 1998; Konvicka et al.,
1998).
Bacteriorhodopsin comprises seven transmembrane seg-
ments, all of which are helical in nature. The greatest
sequence similarities between the GPCRs and bacteriorho-
dopsin are located in these regions, suggesting that the
seven hydrophobic segments in GPCRs are also -helical in
nature (Findlay and Eliopoulos, 1990). Immunological map-
ping and protein digestion studies have provided supporting
evidence for the topography of the receptors, consistent with
seven -helical regions, and have shown the C-terminal
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sequences to be intracellular and the N-terminal sequences
to be extracellular (Dohlman et al., 1987). The N-terminal
sequences are between 10 and several hundred amino acids
in length in different members of the superfamily. The
seven -helical regions are connected by three sets of al-
ternating intracellular and extracellular loops that are usu-
ally between 10 and 40 amino acids in length. The exception
to this is the third intracellular loop, which in some mem-
bers of the superfamily can be more than 150 amino acids in
length. The intracellular C-terminal sequence can also vary
in length from 50 to more than 150 amino acids.
Early models for GPCRs were based on the EM structure
of bacteriorhodopsin (Findlay and Eliopoulos, 1990; Dahl et
al., 1991; Grotzinger et al., 1991; Hibert et al., 1991; Ijzer-
man et al., 1992; Lewell, 1992; Cronet et al., 1993; Sylte et
al., 1993; Yamamoto et al., 1993; Zhang and Weinstein,
1993). Most of these models assumed that the GPCRs had
the same spatial arrangement for the seven helices and the
six loops as bacteriorhodopsin. More recently it has been
suggested that bacteriorhodopsin is not a suitable template
for the construction of GPCR models because functionally
bacteriorhodopsin is not a GPCR and because there is no
overall significant sequence similarity between BR and the
GPCRs (Attwood and Findlay, 1993). Pardo et al. (1992)
suggested that the differences are largely due to exon shuf-
fling, and that similarities between the helices in GPCRs
and BR are observed if the sequential order of the helices is
ignored. Alternatively, Taylor and Agarwal (1993) sug-
gested that gene duplication occurred, which caused helices
five, six, and seven to originate from helices one, two, and
three. Because of the lack of one-to-one correspondence
between the helices, it appears that the BR structure is not
a suitable template for a GPCR model. Further evidence to
this effect is found from the EM projection maps of bovine,
frog, and squid rhodopsins (Schertler et al., 1993; Schertler
and Hargrave, 1995; Davies et al., 1996; Krebs et al., 1998),
which indicate that the arrangement of the helices in the
rhodopsins is indeed different from that in bacteriorhodopsin.
Baldwin (1993) proposed two rules regarding the seven
transmembrane helices, based on over 200 GPCR sequences
and the EM structures. The first rule was that each helix
must be positioned next to its neighbors in the sequence, and
the second rule was that helices one, four, and five must be
the ones most exposed to the lipid surrounding the receptor,
with helix three being the least exposed. Donnelly et al.
(1994) proposed a three-dimensional model of a GPCR
based on Baldwin’s rules and the EM projection map of
bovine rhodopsin. This structure used as a basis the helical
periodicity of amino acid substitution data (Donnelly et al.,
1993). Other models have been produced using automated
techniques based on detailed sequence analyses, multiple
sequence alignments, and interactive graphics packages
(Alkorta and Du, 1994; Taylor et al., 1994). Herzyk and
Hubbard (1995, 1998) proposed a rule-based technique for
packing helices in seven transmembrane helical proteins,
using experimental and theoretical geometric constraint
data. Pogozheva et al. (1997) produced a model that would
maximize the number of interhelical hydrogen bonds for the
entire GPCR superfamily.
Interestingly, although three recent models (Pogozheva et
al., 1997; Baldwin et al., 1997; Herzyk and Hubbard, 1998)
were produced by very different approaches, they exhibit
three important similarities: 1) all have significant tilts in
helices one, two, and three; 2) all model the third helix as
being most deeply buried; and 3) the cytosolic end of helix
three is inserted between helices four and five.
The diverse range of ligands that activate GPCRs appear
to bind to their receptors in one of two ways: they either
bind completely in the transmembrane region or they bind
partly in this region and to part of the extracellular domain.
For example, the adrenaline ligand appears to bind solely in
the transmembrane region of the adrenoreceptor, probably
because of its small size. Ligands of higher molecular
weights (Fong et al., 1993), such as small peptides and
glycolipid hormones, tend to interact with some of the
transmembrane regions as well with an extracellular loop of
the receptor. Within each G-protein-coupled receptor sub-
family it is possible to detect conserved amino acids that
have a role in agonist binding.
Rigid body docking algorithms for predicting protein-
protein interactions tend to take into account shape comple-
mentarity between ligand and receptor, and hydrophobic
effects from the change in the solvent-accessible surface
(Cherfils et al., 1991), matching surfaces (Walls and Stern-
berg, 1992), or geometric complementarity (Norel et al.,
1995). Electrostatic interactions are taken into account in
some algorithms (Walls and Sternberg, 1992), while others
employ Monte Carlo simulations to refine flexible side-
chain positions (Totrov and Abagyan, 1994).
The aim of this study was to produce a model of the ETA
receptor and to use docking algorithms to examine the
manner in which endothelin interacts with its receptor.
METHODS
The modeling described here utilizes a segmented approach where the C
terminus, the N terminus, the transmembrane helices, and the loop regions
were modeled on separate individual templates. The 1BOJ model for
bovine rhodopsin (Pogozheva et al., 1997) was used as a template for the
transmembrane segments. The COMPOSER (Srinivasan and Blundell,
1993) subroutine in SYBYL was used to identify sequence homologs
whose structures were available in the Protein Data Base (PDB), as
possible templates for the N-terminal (water-soluble) domain of the ETA
receptor. Homologs for the three extracellular loops were identified using
a database of loop fragments (Jones and Thirup, 1986; Claessens et al.,
1989) in SYBYL and the criterion of good geometric fit to the anchor
region of the modeled protein. As a more stringent requirement, the loops
identified also had to be located between two helices in the template
structure. ClustalW (Thompson et al., 1994) was then used to determine
which of the loop fragments that met this criterion had the highest homol-
ogy with the ETA loop sequences. PSI-BLAST (Altschul et al., 1997) was
also used in an attempt to identify the loop regions; however, no hits were
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found with an E-value greater than 0.01, probably because the sequences
were too short. When looser constraints were used, the highest scoring
sequences were not of loop regions. Hence, the SYBYL loop search results
were used.
The sequence alignments were undertaken using the ClustalW site
(located at http://www2.ebi.ac.uk/clustalw). The alignments of the ETA
and bovine rhodopsin transmembrane segments correspond to those iden-
tified in the GPCR data base (Horn et al., 1998) (located at http://
www.gpcr.org/7tm). The Blosum scoring matrix (Henikoff and Henikoff,
1992) was used for the BLAST and ClustalW alignments. In ClustalW the
penalty value for closing or opening a gap was set at 10, and the penalty
for extending a gap and separation of a gap was set at 0.05. The statistical
threshold for reporting matches in BLAST was set at 10, and the corre-
sponding cutoff scope for reporting high-scoring segment pairs was cal-
culated from this.
The ends of the transmembrane (TM) segments were defined using the
TMPred algorithm (Hofmann and Stoffel, 1993) (located at http://
www.ch.embnet.org/software/TMPREDform.html). Exceptions to predic-
tions by this algorithm were that the starts of TM2, TM4, and TM6 and the
end of TM3 were modified to mesh with the intracellular loop templates,
and the end of TM6 and the start of TM7 were modified to correspond to
the TM helices in the 1BOJ template.
Once a suitable alignment between the ETA receptor sequence and the
template sequence had been established, SYBYL V.6.4 was used to model
the structure. Nonequivalent amino acids were mutated to produce the ETA
sequence. The loops were positioned with their N and C termini approxi-
mately equidistant from the two end residues of the helices to which they
were to be connected (in all cases, the distance between the loop ends
differed by 1 A from the distance between the target helices). A peptide
bond was then formed with the “join chain” function in SYBYL, and the
six residues surrounding the new bond were minimized. After all connec-
tions were made, the whole structure was energy-minimized using the
Kollman (all-atom) minimization algorithm (Weiner et al., 1984, 1986).
The CONTACT algorithm (Collaborative Computational Project Num-
ber 4, 1994) was used to detect the interhelical hydrogen bonds, and
MODEL (Driessen, unpublished observations) was used to determine the
regions of close intermolecular approach of the polypeptide backbone
atoms. The root mean square deviations were calculated using MOLMOL
(Koradi et al., 1996). The modeled structure was validated with PRO-
CHECK (Laskowski et al., 1993) and WHATIF (Vriend and Sander,
1993).
The FTDOCK (Gabb et al., 1997) algorithm was used to dock the
receptor model with either the endothelin-1 crystal structure (Brookhaven
Protein Data Bank ID, 1EDN) (Janes et al., 1994) or the bigET-1 model
structure (Cronin and Wallace, 1999). The bigET-1 model structure used
had been produced by a combination of homology modeling and threading,
based on NMR and x-ray crystallographic data for ET-1 and a related toxin
structure. FTDOCK was run with electrostatics on, a solvent accessibility
of 10%, and a search over the complete binding space for both molecules.
Negative FTDOCK scores indicate overlap/interpenetration of the ligand
and receptor and are therefore not possible; a score of zero indicates that
the ligand and receptor do not interact at all, and large positive scores
denote complex formation with good surface complementarity. The
NACCESS program (Hubbard and Thornton, 1993) was used to calculate
the solvent accessibility of the modeled receptor and the ligands before and
after docking.
RESULTS
Models for the seven transmembrane regions
The Brookhaven Protein Data Bank (PDB) currently con-
tains two theoretical models of a GPCR. The two models are
of bovine rhodopsin (entries 1BOJ and 1BOK, with trans
and cis retinal ligands, respectively). These models had
been constructed using an iterative distance geometry re-
finement with an evolving system of hydrogen bonds. Over
400 GPCRs were used to produce an average three-dimen-
sional structure for the seven transmembrane helical region;
in these models the numbers of buried polar side chains that
formed hydrogen bonds were maximized for all of the
members of the family simultaneously (Pogozheva et al.,
1997). The resulting structure was consistent with Bald-
win’s for GPCR helix organization. The transretinal bovine
rhodopsin model (PDB ID, 1BOJ) was used as a template
for the seven transmembrane segments of the ETA receptor.
It has significant sequence identity in the transmembrane
regions with the ETA receptor. The sequence alignment of
ETA and bovine rhodopsin is shown in Fig. 1. The percent-
age identities (and similarity—identical plus conservative
substitutions) for each of the seven transmembrane regions
are TM1, 14% (50%); TM2, 23% (77%); TM3, 25% (67%);
TM4, 18% (55%); TM5, 26% (63%); TM6, 29% (52%);
TM7, 16% (52%).
Model for the N-terminal region
The ETA N-terminal sequence of 80 amino acids was ini-
tially tested for sequence homologs of known structure,
using a COMPOSER search. The two candidate template
proteins with the highest sequence identity for the whole
fragment (21%) were aligned with the ETA sequence, using
ClustalW, and the alignment with the smallest number of
gap residues, a hydrolase (carboxylic esterase) (PDB ID,
1HPL) (Lombardo et al., 1989), was chosen as the template.
Its alignment with the ETA N terminus is shown in Fig. 2.
The homologous part of the template protein consists of
three long helices, the first and second of which run nearly
antiparallel to each other. In addition there is a short single-
turn helix between the first and second helices. It should be
noted that the other candidate with 21% homology (PDB
ID, 1OXY) also had a high helix content.
Models for the intracellular loop regions
The intracellular loop regions (Fig. 3 A) were modeled
based on the structures of the intracellular loop regions of
bovine rhodopsin, as determined by NMR spectroscopy
(Yeagle et al., 1995b, 1997). The sequence identities (and
similarities) between each of the intracellular loop regions
of ETA and bovine rhodopsin are as follows: loop 1, 24%
(59%); loop 2, 14% (38%); loop 3, 13% (48%).
Model for the C-terminal region
The C terminus was modeled based on an NMR structure of
the C terminus of bovine rhodopsin (Yeagle et al., 1995a).
The alignment between the C terminus of ETA and the C
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terminus of human rhodopsin (Fig. 3 B) up to the site of
palmitoylation (Cys387) shows a sequence identity of 40%.
Models for the extracellular loop regions
The templates for each of the extracellular loops (EXLs)
were identified according to the following criteria: 1) the
sequence in the template protein had to be of a length
comparable to that of the target loop, 2) the template struc-
ture had to be a loop structure, 3) the template structure had
to form a loop between two antiparallel helical elements, 4)
the distance between the ends of the loop in the template
structure had to differ by no more than 1 Å from the
distance between the TMS to be connected in the target
protein, and 5) the sequence identity of the template protein
with the target protein had to be 20%. For each loop only
one potential template structure was identified in the PDB
that met these stringent criteria. In addition, it was noted
that, in general, the templates and the target sequences
identities included “key residue” types (Martin and Thorn-
ton, 1996) such as glycines, prolines, cysteines, and charged
and large hydrophobic residues. The templates used were as
follows (Fig. 3 C): EXL1 was modeled on 3GLY, which is
a hydrolase protein structure and has a sequence identity to
the ETA loop of 50% (and a similarity of 75%) (Aleshin et
al., 1994). EXL2 was modeled on 1PNE, which is an
actin-binding protein structure and has a sequence identity
with the ETA loop of 21% (similarity of 34%) (Cedergren-
Zeppezauer et al., 1994). EXL3 was modeled on 1PII,
which is an isomerase protein structure and has a sequence
identity with the ETA loop of 25% (similarity of 44%)
(Wilmanns et al., 1992). All loop regions used were checked
to confirm that the loops were well ordered (low B factors
and full occupancies) in the template structure.
FIGURE 2 Sequence alignment of
the N terminus of ETA with 1HPL.
The three helical regions in the tem-
plate and in the model are shown in
bold.
FIGURE 1 Sequence alignment of
the seven transmembrane (TM) seg-
ments of bovine rhodopsin (1boj)
with ETA (eta). In all sequence align-
ment figures, an asterisk (*) indicates
an identical amino acid; a “.” indi-
cates a “conserved” amino acid,
which meets the criteria for either
highly conservative substitutions or
semiconservative substitutions, as de-
fined by ClustalW, using the Gonnet
Pam250 matrix.
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Features of the modeled receptor structure
The structure of the modeled ETA receptor is shown in Fig.
4. The extracellular N terminus contains three helices: Met1-
Phe10; Leu30-Thr55; and Tyr68-Ser77, with a small, single-
turn helix between residues 23 and 25. Preliminary NMR
results by Yeagle and Albert (1999) on the isolated rhodop-
sin N terminus indicate that it also contains helical seg-
ments. Although the rhodopsin N terminus is only about
half the length of the ETA receptor N terminus, it also has
one long helix near the beginning, followed by a short,
single-turn helix. Hence some similar structural motifs may
be present in the N termini of these two GPCRs.
The seven transmembrane helices were modeled in the
following regions of the protein, using the sequence align-
ment shown in Fig. 1: TM1, Tyr81-Leu102; TM2, Ala120-
Leu142; TM3, Leu160-Arg183; TM4, Ile206-Val227; TM5,
Trp257-Met278; TM6, Leu311-Thr331; TM7, Leu348-Val372.
The fourth sixth and seventh transmembrane helices are
approximately parallel to each other, whereas the other four
helices are tilted. A proline kink is present at Pro267 in the
fifth transmembrane helix (as it is in the corresponding part
of the template protein). The root mean square deviations
between backbone atoms in each of the TM segments of the
rhodopsin template and the ETA model ranged from 0.15 to
0.84 Å2, with the largest variation being found in TM6. A
preponderance of aromatic amino acids is located at or near
the ends of many of the transmembrane segments (a feature
previously noted in the crystal structures of many other
membrane proteins; (Deisenhofer and Michel, 1989; Wal-
lace and Janes, 1999)).
The intracellular C terminus was modeled as a compact
globular structure. There is sequence conservation between
the two rhodopsin cysteines (at positions 322 and 323) and
the two ETA cysteines (at positions 385 and 386). In rho-
dopsin these two cysteines can be acylated; however, in the
NMR structure (Yeagle et al., 1995a), the C terminus was
found to be a compact structure even in the absence of
cysteine acylation. The last 40 amino acids of the C termi-
nus of ETA have not been modeled in this study because
there was insufficient sequence homology to construct a
model.
The three modeled cytoplasmic loops have -turns in the
middle, as in the rhodopsin templates on which they were
modeled. The ends of all of the extracellular and intracel-
lular loops were separated by distances that enabled them to
be annealed to their corresponding helices.
FIGURE 3 Sequence alignments
of ETA with (A) bovine rhodopsin
intracellular loops, (B) C-terminus
(up to Cys387) and (C) loops of
3GLY, 1PNE, and 1PII.
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The PROCHECK statistics showed that 87% of the res-
idues in the ETA model are in either the most favored or in
the additionally allowed regions of the Ramachandran plot.
The overall main-chain and side-chain parameters, as eval-
uated by PROCHECK are all very favorable. The WHATIF
validation found loose rms Z-scores, which are typical of
model, as opposed to experimental, structures.
Ligand docking
Changes in accessible surface area were used to demon-
strate regions of binding. Although the magnitudes of the
changes are susceptible to minor changes in the side-chain
conformations, which are not reliably known for these mod-
eled structures, this physical characteristic does clearly in-
dicate which residues are in most intimate contact. Thus, as
a conservative approach, we have only highlighted the res-
idues that exhibit the largest changes in their surface areas
as being regions of contact. Supporting this is the observa-
tion that similar groups of residues are indicated as being
involved in the intermolecular interactions if other measure-
ments of close approach (such as those involving intramo-
lecular backbone distances of 5 Å) are used.
Fig. 5 shows the predicted docking of endothelin-1 into
the modeled ETA receptor. The highest positive correlation
score structure ( 176) predicted by FTDOCK is the one
shown. All other highly positively scored structures were
also in this region. The change in accessible surface area of
the ETA receptor model with and without ET-1 docked is
1100 Å2 or 4% of the total surface area, indicative of a
substantial interaction. Furthermore, the majority of the
changes are mapped (Tables 1–4) to the extracellular ends
of the TM segments involved (1, 2, and 7), as well as EXL1,
and to a lesser extent EXL2 and part of the N terminus. In
the TM segments, only one face of each helix tends to be
involved, thus defining their orientations. No interactions
FIGURE 4 The modeled ETA receptor, drawn as a ribbon diagram with
MOLMOL (Koradi et al., 1996).
TABLE 1 Accessible surface area of the first 10 residues on
the extracellular side of TM1
Residue
Accessible surface
area of free ETA
(A2)
Accessible surface
area of ETA with
bound ET-1 (A2)
Tyr81 121 117
Ile82 102 102
Asn83 31 19
Thr84 35 35
Val85 93 93
Ile86 64 64
Ser87 1 1
Cys88 65 65
Thr89 79 79
Ile90 29 29
In Tables 1–5, * in the right-hand column denotes amino acids with the
largest changes between the free receptor or ligand and the receptor
complex.  indicates ones with smaller changes.
FIGURE 5 Predicted docking of the endothelin-1 crystal structure
(drawn in dark blue in stick mode) to the modeled ETA receptor (drawn as
in Fig. 4).
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were found with TM 3, 4, 5, or 6, any of the intracellular
loops, or the C terminus.
Fig. 6 shows the highest correlation structure predicted
for the docking of the endothelin precursor (bigET-1) and
the ETA receptor, which had a very small score of 28. That
is, essentially no interaction between the receptor model and
the modeled structure of bigET-1 is observed. There was no
change in the accessible surface area of the modeled recep-
tor when the proposed complex with bigET docked was
analyzed. The “docked” structures with the next 20 highest
scores also did not show binding to the receptor.
DISCUSSION
This study took a segmented approach to modeling a GPCR.
Such a procedure is only justified if there is evidence that
the individual segments in GPCRs can fold independently.
For rhodopsin, it has been shown that the C-terminal region
and the intracellular loops form compact structures that
retain functional activity when examined as isolated
polypeptides (Yeagle et al., 1995a,b, 1997). Furthermore,
Martin et al. (1999) have recently shown that various TM
segments of the -factor receptor can fold and assemble into
functional forms independent of the loop segments.
The TM segment template used in this study (Pogozheva
et al., 1997) was constructed by a procedure that would
produce the highest possible number of interhelical hydro-
gen bonds for the entire GPCR superfamily, although it did
not necessarily maximize the number of hydrogen bonds in
a individual member of the family. There are nine interheli-
cal hydrogen bonds involving side chains between TM
helices in the ETA model structure; there were six such
hydrogen bonds in the equivalent regions of the template
structure. The model produced is consistent with prelimi-
nary circular dichroism data on refolded ETA (Crawford and
Wallace, unpublished results), which suggests that it has
50% helix content, in contrast to bacteriorhodopsin,
which is 80% helical (Wallace and Teeters, 1987). This
lower overall helix content is obviously due to the larger
nonhelical loops and termini found in the ETA receptor.
The x-ray crystal structure of ET-1 (Janes et al., 1994)
was used in the docking studies with the ETA receptor.
Structures of ET-1 and its analogs have also been deter-
mined by NMR spectroscopy (Endo et al., 1989; Saudek et
al., 1989; Krystek et al., 1991; Munro et al., 1991; Reily and
Dunbar, 1991; Tamaoki et al., 1991; Andersen et al., 1992).
The NMR structures differ substantially, both from each
other and from the x-ray structure (Wallace et al., 1995),
especially in the all-important C terminus, a region that is
disordered in many of the NMR structures. No NMR struc-
tures of ET-1 that include the C terminus have been depos-
ited in the PDB, and hence none were available for docking
studies. Justification for using the crystal structure, how-
ever, derives not from availability, but from the structure-
activity relationship (SAR) studies that have been done on
ET-1 (for a review, see Huggins et al., 1993), including
alanine scans (Tam et al., 1994). When residues Glu10,
Phe14, Asp18, and Trp21 are mutated to almost any other
amino acid, vasoactivity function (and hence receptor bind-
TABLE 3 Accessible surface area of the first 10 residues on
the extracellular side of TM7
Residue
Accessible surface
area of free ETA
(A2)
Accessible surface
area of ETA with
bound ET-1 (A2)
Leu348 93 10*
Leu349 32 1*
Met350 80 62
Asp351 47 47
Tyr352 33 14
Ile353 88 38*
Gly354 8 8
Ile355 10 10
Asn356 7 7
Leu357 85 85
TABLE 4 Accessible surface area of EXL1 residues
Residue
Accessible surface
area of free ETA
(A2)
Accessible surface
area of ETA with
bound ET-1 (A2)
Ala143 60 60
Gly144 40 40
Arg145 170 170
Trp146 141 141
Pro147 115 115
Phe148 158 158
Asp149 26 26
His150 164 158
Asn151 102 101
Asp152 112 110
Phe153 142 40*
Gly154 37 8*
Val155 64 48
Phe156 205 118*
Leu157 147 147
Cys158 79 79
TABLE 2 Accessible surface area of the first 10 residues on
the extracellular side of TM2
Residue
Accessible surface
area of free ETA
(A2)
Accessible surface
area of ETA with
bound ET-1 (A2)
Leu142 144 43*
Leu141 83 77*
Lys140 40 37
Phe139 59 59
Val138 95 95
Asn137 5 5
Ile136 12 12
Pro135 37 37
Leu134 66 66
Asp133 0 0
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ing) is dramatically decreased. This pattern of significant
substitutions separated by three or four residues is indicative
of a helical secondary structure, which would place these
amino acids on the same surface (Wallace and Janes, 1995).
Such a helical secondary structure is found only in the x-ray
crystal structure—hence its use in these studies. In the
docked complex, the C terminus of the ligand shows a
pattern of maximum changes in accessible surface area
involving residues 10, 13, 14, 17, 18, and 21 (Table 5), the
same sort of helical repeating pattern, which is nearly iden-
tical to the residues indicated to be the most important by
SAR studies. N-terminal residues also clearly interact with
the receptor, but this region appears to be associated with
specificity of binding rather than binding affinity (Huggins
et al., 1993).
Mutational studies of the ETA receptor have suggested
receptor residues that may be involved in ligand binding
(for example, Adachi et al., 1994; Krystek et al., 1994; Breu
et al., 1995; Rose et al., 1995; Webb et al., 1996). These are
compiled in the tinyGRAP (Kristiansen et al., 1996; Ed-
vardsen and Kristiansen, 1997) mutant database (Rel. 6.0).
It is not expected that all of the mutations that cause binding
effects will be at actual sites of contact in the complex.
Many may be folding mutants that alter the receptor’s
overall conformation but not specifically its binding site.
Indeed, many of the TinyGRAP sites in the TM segments
appear to be buried and thus likely modulate the packing
and ultimately the folding of the receptor itself. Further-
more, there is a very broad spatial distribution of the resi-
dues implicated in binding. Some clearly cannot involve the
actual binding site, given their distance from each other and
even their apparent locations on distal sides of the mem-
brane. While the situation is complicated, those mutants that
appear to specifically affect ET-1 binding (as opposed to
other effects, such as antagonist binding or specificity for
endothelin isoforms) seem to be concentrated in TM2, TM7,
and EXL1. A number of the residues between 132 and 156
appear to be especially important for the binding function.
In the receptor complex produced in these studies, as indi-
cated by a decrease in the accessible surface areas of various
FIGURE 6 The “undocked” modeled bigET-1 structure with the ETA
receptor (drawn as in Fig. 5). The view in this figure is rotated about the
x axis by70° relative to the views in Figs. 4 and 5, for the ligand “binding
site” to be visible.
FIGURE 7 Schematic diagram showing where the ligand (indicated as a
hatched oval) binds. This is an end-on view of the seven transmembrane
helices of the receptor, with each helix drawn as a circle.
TABLE 5 Accessible surface area of the ET-1 ligand
Residue
Accessible surface
area of free ET-1
(A2)
Accessible surface
area of ET-1
bound to ETA
(A2)
Cys1 114 84
Ser2 107 49*
Cys3 75 34*
Ser4 26 27
Ser5 87 46*
Leu6 164 13*
Met7 116 59*
Asp8 119 52*
Lys9 170 95*
Glu10 96 41*
Cys11 4 4
Val12 38 26
Tyr13 185 14*
Phe14 90 31*
Cys15 14 13
His16 96 80
Leu17 95 23*
Asp18 123 79*
Ile19 122 124
Ile20 101 74
Trp21 230 75*
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residues, the ligand docks principally at the extracellular
ends of TM1, TM2, and TM7 of the receptor (Tables 1–3)
as well as EXL1 (Table 4) and, to a lesser extent, EXL2 and
part of the N terminus. Residues 140–156 are clearly in-
volved in the binding interaction. The location of the bind-
ing site is shown schematically in Fig. 7, a view looking
down onto the receptor from the extracellular side.
The proposed interactions of the ET-1 ligand in the ETA
receptor-binding pocket are shown in Fig. 8. The residues
that are involved in the closest contacts and have been
indicated to be important for ligand binding to the ETA
receptor (Huggins et al., 1993) are explicitly shown.
Fig. 6 shows the results obtained for the prediction of the
docking of bigET and the ETA receptor, as a control for the
docking procedure used. Biochemical evidence (NDiaye et
al., 1997) indicates that bigET-1 exhibits negligible biolog-
ical activity at the receptor, and hence it is believed not to
be able to bind in the ligand-binding site. The in vivo
pressor effect, an indirect measure of binding affinity, sug-
gests 100-fold lower potency for bigET-1 relative to ET-1
(Kimura et al., 1989). Correspondingly, in this modeling
study, essentially no interaction between the receptor and
the modeled structure of bigET-1 was observed. The bigET
structure is too bulky to interact with the receptor in the
region occupied by ET-1 because of the size restraints
caused by the extracellular loop regions of the ETA receptor.
Furthermore, the C-terminal precursor extension on
bigET-1 (residues 22–38) tends to block a number of the
helical residues that appear to be involved in the binding,
namely residues 10, 17, 18, and 21.
This model now permits us to predict the binding of an
endothelin analog, the precursor BigET(1–31). At present it
has been speculated that this molecule might bind to the
receptor, but there is no experimental evidence to support or
refute this. Using the same type of procedure for docking as
described above, it was found that this molecule could bind
in approximately the same site as the mature ET-1, although
the extent of interaction with ETA was less (score  63).
This would predict binding, but perhaps with a lower affin-
ity, a testable hypothesis.
In summary, now that we have a working model for the
receptor-ligand complex, it should be possible to design
biochemical and mutational studies to test the interactions
proposed and to design other molecules that may fit in the
binding pocket and act as agonists or antagonists.
Note added after submission of this paper
Since this paper was first submitted, the crystal structure of a GPCR,
rhodopsin, was published (Palczewski et al., 2000). In general, the overall
structures of that and the model in this work are similar, and the RMSDs
between the backbone atoms of each of the TMS segments of that structure
and our model were 2.0 Å. There are significant differences in the N
termini. These parts of the molecules, however, are not expected to be very
similar, because the length of the N terminus of rhodopsin is only 1/2 of
that of ETA receptor, and there is little sequence homology between the
two.
This work was supported by a grant from the British Heart Foundation. AO
was the recipient of a Biotechnology and Biological Science Research
Council studentship.
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